Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00487136 · ClinicalTrials.gov registry record · Phase 1
Interaction Between ABT-335, Rosuvastatin and Warfarin
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00487136 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 45 participants.
The verdict
NCT00487136, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in adult male subjects in general good health.
Interventions
- DRUG Warfarin
- DRUG warfarin plus ABT-335 plus rosuvastatin 5 mg
- DRUG warfarin plus ABT-335 plus rosuvastatin 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00487136
The ClinicalTrials.gov registry entry for NCT00487136 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Warfarin is the first listed.
NCT00487136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00487136 about?
NCT00487136 is a clinical study titled "Interaction Between ABT-335, Rosuvastatin and Warfarin". This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in adult male subjects in general good health.
What is the current status of trial NCT00487136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2007-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00487136?
The interventions under investigation include: Warfarin (DRUG), warfarin plus ABT-335 plus rosuvastatin 5 mg (DRUG), warfarin plus ABT-335 plus rosuvastatin 20 mg (DRUG).
Who is sponsoring clinical trial NCT00487136?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.